Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 65

1.

The Stem Cell Hard Sell: Report from a Clinic's Patient Recruitment Seminar.

Knoepfler PS.

Stem Cells Transl Med. 2017 Jan;6(1):14-16. doi: 10.5966/sctm.2016-0208.

2.

To CRISPR and beyond: the evolution of genome editing in stem cells.

Chen KY, Knoepfler PS.

Regen Med. 2016 Dec;11(8):801-816.

PMID:
27905217
3.

The Stem Cell Hard Sell: Report From a Clinic's Patient Recruitment Seminar.

Knoepfler PS.

Stem Cells Transl Med. 2016 Aug 2. pii: sctm.2016-0208. [Epub ahead of print]

4.

When patients reach out, scientists should reach back carefully.

Knoepfler PS.

Nat Med. 2016 Mar;22(3):230. doi: 10.1038/nm0316-230. No abstract available.

PMID:
26937614
5.

From bench to FDA to bedside: US regulatory trends for new stem cell therapies.

Knoepfler PS.

Adv Drug Deliv Rev. 2015 Mar;82-83:192-6. doi: 10.1016/j.addr.2014.12.001. Review.

6.

Histone H3.3 regulates dynamic chromatin states during spermatogenesis.

Yuen BT, Bush KM, Barrilleaux BL, Cotterman R, Knoepfler PS.

Development. 2014 Sep;141(18):3483-94. doi: 10.1242/dev.106450.

7.

Miz-1 activates gene expression via a novel consensus DNA binding motif.

Barrilleaux BL, Burow D, Lockwood SH, Yu A, Segal DJ, Knoepfler PS.

PLoS One. 2014 Jul 1;9(7):e101151. doi: 10.1371/journal.pone.0101151. Erratum in: PLoS One. 2014;9(9):e108565.

8.

Epigenetic mechanisms of tumorigenicity manifesting in stem cells.

Tung PY, Knoepfler PS.

Oncogene. 2015 Apr 30;34(18):2288-96. doi: 10.1038/onc.2014.172. Review.

9.

Histone H3.3 mutations: a variant path to cancer.

Yuen BT, Knoepfler PS.

Cancer Cell. 2013 Nov 11;24(5):567-74. doi: 10.1016/j.ccr.2013.09.015. Review.

10.

Key action items for the stem cell field: looking ahead to 2014.

Knoepfler PS.

Stem Cells Dev. 2013 Dec;22 Suppl 1:10-2. doi: 10.1089/scd.2013.0322.

11.

Scientists: you really need to get out of the lab more.

Knoepfler PS.

Nat Med. 2013 Sep;19(9):1086. doi: 10.1038/nm0913-1086. No abstract available.

12.

Chromatin immunoprecipitation assays for Myc and N-Myc.

Barrilleaux BL, Cotterman R, Knoepfler PS.

Methods Mol Biol. 2013;1012:117-33. doi: 10.1007/978-1-62703-429-6_9.

13.

Identification of DPPA4 and DPPA2 as a novel family of pluripotency-related oncogenes.

Tung PY, Varlakhanova NV, Knoepfler PS.

Stem Cells. 2013 Nov;31(11):2330-42. doi: 10.1002/stem.1526.

14.

Myc binds the pluripotency factor Utf1 through the basic-helix-loop-helix leucine zipper domain.

Laskowski AI, Knoepfler PS.

Biochem Biophys Res Commun. 2013 Jun 14;435(4):551-6. doi: 10.1016/j.bbrc.2013.04.100.

15.

Endogenous mammalian histone H3.3 exhibits chromatin-related functions during development.

Bush KM, Yuen BT, Barrilleaux BL, Riggs JW, O'Geen H, Cotterman RF, Knoepfler PS.

Epigenetics Chromatin. 2013 Apr 9;6(1):7. doi: 10.1186/1756-8935-6-7.

17.

Utf1: Goldilocks for ESC bivalency.

Laskowski AI, Knoepfler PS.

Cell Stem Cell. 2012 Dec 7;11(6):732-4. doi: 10.1016/j.stem.2012.11.012.

18.

Induced pluripotent stem cells show metabolomic differences to embryonic stem cells in polyunsaturated phosphatidylcholines and primary metabolism.

Meissen JK, Yuen BT, Kind T, Riggs JW, Barupal DK, Knoepfler PS, Fiehn O.

PLoS One. 2012;7(10):e46770. doi: 10.1371/journal.pone.0046770.

19.

Induced pluripotency and oncogenic transformation are related processes.

Riggs JW, Barrilleaux BL, Varlakhanova N, Bush KM, Chan V, Knoepfler PS.

Stem Cells Dev. 2013 Jan 1;22(1):37-50. doi: 10.1089/scd.2012.0375.

20.

Key anticipated regulatory issues for clinical use of human induced pluripotent stem cells.

Knoepfler PS.

Regen Med. 2012 Sep;7(5):713-20. doi: 10.2217/rme.12.51. Review.

Supplemental Content

Loading ...
Support Center